RecruitingNot ApplicableNCT06863545

Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

3,596 participants

Start Date

Apr 22, 2025

Study Type

INTERVENTIONAL

Conditions

Coronary Artery Disease Cardiovascular Events CT Angiography PCSK9

Summary

The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography (CCTA)-detected high-risk plaques.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called PCSK9 inhibitors and background lipid-modifying therapy and a drug called Standard lipid-modifying therapy for people with ct angiography, cardiovascular events, and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPCSK9 inhibitors and background lipid-modifying therapy

Patients will receive subcutaneous injections of PCSK9 inhibitors and oral administration of background LMT (including statins and/or cholesterol absorption inhibitors) for the first 12 months after randomization, with PCSK9 inhibitors administered every 2 weeks. After the first 12 months, patients will discontinue the PCSK9 inhibitors but continue background LMT for the remainder of the trial.

DRUGStandard lipid-modifying therapy

Patients will receive standard LMT commonly used in clinical practice.